Evidence map›Paper›PMID 24723677›Full record

ArticleBlood2014

A WHIM satisfactorily addressed.

Hal E Broxmeyer

Abstract readComment
PubMed Publisher
In one paragraph

Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Hal E BroxmeyerINDIANA UNIVERSITY SCHOOL OF MEDICINE.
University School · US

Funding

MECHANISMS OF SYNERGISTIC REGULATION OF STEM/PROGENITORSR01HL056416 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI BROXMEYER, HAL E. · 1996 to 2017
$6.0M
Cytokine Enhancement of Myeloid Progenitor Cell SurvivalR01HL067384 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI BROXMEYER, HAL E. · 2001 to 2014
$4.6M
Enhancing Engraftment of Cord Blood by CD26 InhibitionR01HL112669 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI BROXMEYER, HAL E., FARAG, SHERIF S · 2012 to 2016
$3.6M
NHLBI NIH HHS R01 HL056416NHLBI NIH HHS R01 HL067384NHLBI NIH HHS R01 HL112669
6 · The paper itself

Abstract

In this issue of Blood, McDermott et al present the intriguing, clinically relevant, and perhaps unexpected findings for the efficacy and safety of long-term administration of low-dose plerixafor treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome.

Indexed as

BenzylaminesCyclamsFemaleHeterocyclic CompoundsHumansImmunologic Deficiency SyndromesMalePrimary Immunodeficiency DiseasesReceptors, CXCR4WartsBenzylaminesCXCR4 protein, humanCyclamsHeterocyclic CompoundsplerixaforReceptors, CXCR4

Identifiers

PMID24723677
OpenAlexW1983819980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.